OUR COMPANY
RARE PHARMA-GRADE BARIUM SULFATE AND IODINE IN NORTH AMERICA
- Voyageur Pharmaceuticals Ltd. (VM: TSX-V, OTC: VVYRF, Forum) is developing its 100% owned high grade barium sulfate project in BC, Canada.
- VM business plan is to develop its advanced stage pharmaceutical grade barium sulfate project, Frances Creek. Voyageur is developing barium contrast radiographic suspension products for the pharmaceutical industry.
- Frances Creek bulk sample tentatively scheduled for Q3, 2021
- VM’s pharmaceutical grade barite is naturally occurring with grades as high as 99.26% BaSO4 in-situ, which is very rare.
- Voyageur has achieved a 98.6% BaSO4 product with SGS Minerals. The only barite sold in the market place, grading +98%, is man made in a lab using an expensive manufacturing processing.
- The only other source of natural pharmaceutical grade barite is from China.
- China only exports 5% of their production of pharmaceutical barite, allocating 95% for their domestic market.
- The pharmaceutical industry primarily uses expensive man made barium sulfate for the radiographic market.
Investor Intel-Voyageur Milestones
https://investorintel.com/markets/biotech-healthcare/biotech-intel/voyageur-pharmaceuticals-completes-fda-submission-milestone-for-first-barium-contrast-product-license-application/
Voyageur Pharmaceuticals Completes Milestone with the FDA and Continues to Move Towards Commercialization on Three Fronts
Voyageur Pharmaceuticals FDA-Progress May 18 2022
Buy rating increased to $0.55/share- Fundamental Research Corp
Voyageur-Mar-2022-Update